创新药猛攻，高纯度+高弹性标的——港股通创新药ETF（520880）摸高4．6%！机构：国际化提速打开成长空间

Core Viewpoint - The Hong Kong stock market is experiencing a rebound, particularly in the innovative pharmaceutical sector, with significant trading activity in the Hong Kong Innovative Drug ETF (520880) [1] Group 1: Market Performance - The Hong Kong Innovative Drug ETF (520880) saw an intraday price increase of over 4.6%, currently up by 3.25%, with a trading volume nearing 500 million [1] - The Hang Seng Innovative Drug Index has risen by 101.58% year-to-date as of July 31, significantly outperforming the Hang Seng Index and Hang Seng Tech Index by 78.08% and 79.53% respectively [6] Group 2: Company Highlights - China National Pharmaceutical Group reported a 27.2% year-on-year increase in revenue from innovative products, which now account for 44.4% of total revenue, with nearly 20 innovative products expected to be approved between 2025 and 2027 [2] - Innovent Biologics announced FDA approval for its PD-1/IL-2α bispecific antibody IBI363 to commence global Phase III clinical trials for squamous NSCLC [2] Group 3: Industry Outlook - According to China International Capital Corporation, the domestic market for innovative drugs is expected to grow significantly, with a projected revenue of 446 billion by 2030 based on a 30% compound annual growth rate [3] - The overseas market for domestic innovative drugs has seen cumulative contract amounts reaching 193.8 billion, with conservative estimates suggesting potential sales contributions of 14.5 billion [3] - The innovative drug sector is characterized by strong industry trends and investment value, supported by policy initiatives and an accelerating internationalization process [3] Group 4: Stock Performance - Major stocks in the innovative pharmaceutical sector, such as CSPC Pharmaceutical Group and Innovent Biologics, have seen price increases exceeding 6%, while others like China National Pharmaceutical and 3SBio have risen over 5% [4]